LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission to Special Examination and Approval Procedure for Innovative Medical Devices in respect of Thoracoabdominal Artery Stent Graft System

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 9 November 2021, the Company obtained formal written notice from the National Medical Products Administration ("**NMPA**") confirming the admission of Thoracoabdominal Artery Stent Graft System (the "**Product**") into NMPA Special Examination and Approval Procedure for Innovative Medical Services (藥監局創新醫療器械特別審查程序) (the "**Procedure**"). The Product is the 14th product of the Company having obtained admission to the Procedure.

The Product is suitable for the endovascular treatment of thoracic and abdominal aortic aneurysms. This innovative product offers a solution to the global problem of intra-luminal reconstruction of multi-branch arteries. It can achieve complete intra-luminal reconstruction of visceral vessels and maintain continuous blood supply to all organs during the operation. The stent graft is an off-the-shelf aortic endo-prosthesis with two proximal inner branches for the celiac axis (CA) and superior mesenteric artery (SMA) and two distal side directional branches for the bilateral renal arteries. The outlet orifice of the four branch stents are designed to be of the same level as the orifice of visceral vessels in order to reconstruct the visceral vessels. The endoprosthesishas has an adequate proximal landing zone to effectively reduce the risk of type I internal leakage. The design of the Product also eases surgical procedures: the radiopaque markers around the inlets and outlets of all the

portals can be clearly displayed under fluoroscopy. The proximal two portals for the inner branches are preloaded with wires to assist cannulation of the visceral vessels. In addition, the graded-release design of the pathologies allows the surgeon to adjust its position conveniently, allowing for more accurate positioning.

The Product has a wide range of indications for use in more anatomically complex cases and can be adapted to visceral vessels of different diameters. The proximal and distal ends of the main stent can be extended according to the patient's condition to meet different treatment needs.

The Board believes that the admission of the Product into the Procedure will shorten the registration process of the Product, whereby expediting its launch process. It is expected that the launch of the Product will benefit patients requiring endovascular reconstruction of thoracic and abdominal aortic aneurysms while enriching the Group's product portfolio and fostering the Group's development in medical devices.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 10 November 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.